Potential association of and variant alleles with increased risk for palbociclib toxicity.

This study evaluated associations between and variants in other pharmacogenes (, , , , ) and the risk for palbociclib-associated toxicities. Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively. No significant associations were found for , , _rs1045642, _rs2231142, _rs3212986 and _rs11615. Homozygous variant carriers of _rs182420 had higher incidence of dose modifications due to palbociclib toxicity (odds ratio [OR]: 4.334, 95% CI: 1.057-17.767,  = 0.042). variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR: 4.14, 95% CI: 0.99-17.37,  = 0.052). Once validated, and variants may be useful to individualize palbociclib dosing to minimize toxicities and improve treatment outcomes.